Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab SC Administration Method (Manual Push vs Syringe Driver) in Healthy Participants
NCT04828343Phase 1Completed
- Sponsor
- UCB
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rozanolixizumab in myasthenia gravis (MG) (4 cohorts), sponsored by UCB. Primary endpoint: Treatment-emergent Adverse Events at Day 57. Started Apr 2021; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04828343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04828343.